KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.80

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Emanuele Zucca, Luca Ceriani, Giovannino Ciccone, Alice Di Rocco, Maria Cristina Pirosa, Iryna Kriachok, Barbara Botto, Monica Balzarotti, Alessandra Tucci, Sara Veronica Usai, Vittorio Ruggero Zilioli, Elsa Pennese, Luca Arcaini, Anna Dabrowska-Iwanicka, Andrés J M Ferreri, Francesco Merli, Weili Zhao, Luigi Rigacci, Claudia Cellini, David Hodgson, Codruta Ionescu, Carla Minoia, Elisa Lucchini, Michele Spina, Alexander Fosså, Andrea Janikova, Kate Cwynarski, N George Mikhaeel, Mats Jerkeman, Anastasios Stathis, Kelly Cozens, Nicoletta Ielmini, Iolanda De Martino, Jan Walewski, Marek Trneny, Franco Cavalli, Umberto Ricardi, Peter W M Johnson, Andrew Davies, Maurizio Martelli

Blood 146(23) 2758-2764

PMID40939190
PMCID-
DOI10.1182/blood.2025028823
发表日期2025-09-12
入排依据:The record is an original results report from a Phase III oncology trial with drug interventions and time-to-event endpoints. However, it is a secondary analysis comparing outcomes of different regimens chosen by local practice, not the primary report. Critically, the record does not explicitly establish that patients were randomly assigned to the different regimens being compared (R-CHOP21 vs others). Therefore, the 'randomized' criterion for this specific analysis cannot be confirmed, making it ineligible for the cohort requiring clear randomization evidence.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

The IELSG37 trial enrolled 545 patients with primary mediastinal B-cell lymphoma (PMBCL) and demonstrated that consolidation radiotherapy (RT) can be omitted in patients with complete metabolic response, defined by the Lugano classification as Deauville score (DS) 1 to 3. This report evaluates outcomes after different frontline rituximab- and doxorubicin-based immunochemotherapy regimens chosen according to local practice. Patients treated with R-CHOP21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, administered every 21 days) showed a significantly higher percentage of DS 5 than those on other regimens (23.8% vs 8.2% average; P < .001) and a trend toward additional unplanned treatments (53.2% vs 46.9%; P = .30). The increased risk of poor response was confirmed in a multinomial logistic regression analysis adjusted for age, sex, international prognostic index score, and performance status. R-CHOP21 was also associated with smaller reductions in metabolic tumor volume and less pronounced decreases in maximum standardized uptake value. Patients with DS 5 more often received additional treatment (RT and/or salvage chemotherapy with or without autologous consolidation) after induction immunochemotherapy (96% vs 41%; P < .001) and experienced significantly poorer outcomes. Although differences in progression-free and overall survival between R-CHOP21 and more aggressive regimens were not statistically significant, R-CHOP21 may increase the risk of additional treatments and may be inadvisable as frontline therapy for PMBCL. This trial was registered at www.clinicaltrials.gov as #NCT01599559.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。